Investors / Monaco / 3B Future Health Fund
3B Future Health Fund
Venture capital · Monaco, Monaco · Europe
3B Future Health Fund is a venture capital fund that invests in private early-stage healthcare companies developing novel therapies. It was launched in 2016 by Riccardo Braglia and a team of pharmaceutical industry experts, and its second fund focuses on oncology and rare disease therapeutics.
Invests inHealthcare & Biotech
In its own wordsoncologyrare diseasesbiotechtherapeuticshealthcaredrug development
Your fit with 3B Future Health Fund
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fits3B Future Health Fund lists 9 checked portfolio companies on its own site and is named in 2 funding rounds. Its most frequent entry is Series B, 50% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). It invests most often alongside Flerie, Novartis Venture Fund and ALSA Ventures.
Counts come from funding rounds that name 3B Future Health Fund, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 0% |
| Series B | 50% |
| Growth | 50% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 1 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 19th | 9 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 78th | 5 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Flerie | 2 |
| Novartis Venture Fund | 2 |
| ALSA Ventures | 1 |
| AlbionVC | 1 |
| Astellas Venture Management | 1 |
| Axil Capital | 1 |
| BioGeneration Ventures | 1 |
| CTI Life Sciences Fund | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers9100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare 3B Future Health Fund head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with 3B Future Health Fund| Date | Company | Stage |
|---|---|---|
| 10 Feb 2026 | Series B | |
| 22 May 2025 | Series C+ |
Round details for 3B Future Health Fund
Amounts, full round histories and every co-investor in 3B Future Health Fund's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
9 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| AnaCardio is developing novel drugs to treat heart failure | Healthcare & Biotech | Portfolio page | ||
| Domain Therapeutics develops breakthrough GPCR-targeting therapies for patients, especially in immuno-oncology and inflammation. | Healthcare & Biotech | Feb 2026Series B | Funding round | |
| Epsilogen is a company that discovers and develops immunoglobulin IgE, IgA and IgG-based therapeutics for the treatment of cancer | Healthcare & Biotech | Portfolio page | ||
| Fore Biotherapeutics develops targeted therapies for treating cancers. | Healthcare & Biotech | May 2025Series C+ | Funding round | |
| Geneos Therapeutics develops DNA-based personalized immunotherapies for cancer | Healthcare & Biotech | Portfolio page | ||
| GreenBone provides innovative solutions for bone regeneration | Healthcare & Biotech | Portfolio page | ||
| iOnctura develops therapies for cancer and other diseases. | Healthcare & Biotech | Portfolio page | ||
| NeoPhore develops a therapeutic approach that blocks DNA Mismatch Repair to make tumors sensitive to immunotherapy. | Healthcare & Biotech | Portfolio page | ||
| QuantuMDx develops and provides diagnostic technologies and products for point-of-need multiplex diagnostics | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- 3bfuturehealth.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 22 May 2025
- Companies checked
- 9
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get 3B Future Health Fund's profile as data
Pull 3B Future Health Fund's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/3bfuturehealth.com
# also
GET /v1/firms/3bfuturehealth.com/portfolio
GET /v1/firms/3bfuturehealth.com/coinvestors
GET /v1/firms/3bfuturehealth.com/news